10 years ago

Immunocore Secures $320 Million to Advance Cancer Treatment Technologies

  • Immunocore, a UK-based biotechnology company specializing in developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, closed a US$320 million financing round

  • The funding will be used to accelerate the company's pipeline of ImmTACs (Immune mobilising mTCR Against Cancer)

  • The round was led by new investors Woodford Investment Management, Malin Corporation plc, Eli Lilly and Company, and RTW Investments.

      • ProblemHealthcare

      "Patients with advanced metastatic cutaneous and ocular melanoma need effective treatment options, but current treatments are limited and often have severe side effects."

      Solution

      "Immunocore is developing a new class of cancer therapies called ImmTACs, which are designed to specifically target and kill cancer cells while sparing healthy cells. This approach has the potential to provide a more effective and tolerable treatment for patients with advanced melanoma and other cancers."

      Covered on